Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy? [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Occasionally, some pharmaceutical companies hit the jackpot and launch medicines worth all that trouble. That's what Eli Lilly (NYSE: LLY) has on its hands with tirzepatide, marketed as Mounjaro in the diabetes market and as Zepbound to help with weight loss. Analysts predict that tirzepatide's peak sales could reach $25 billion, but to get there, Eli Lilly will have to earn more indications for its new crown jewel. One exciting market the drugmaker is targeting is the non-alcoholic steatohepatitis (NASH) field. Read on to find out what makes this area promising for Eli Lilly's tirzepatide and what it means for the stock. There is a large unmet need in NASH NASH is a liver disease that, as its name suggests, is not due to heavy alcohol consumption. It is caused by a buildup of fat in the liver that leads to fibrosis (scarring). Diabetes and obesity are among the leading risk factors for NASH, which, in severe cases, can be deadly. Here's the thing: The prevalence of diabetes and
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy [Seeking Alpha]Seeking Alpha
- 2 Reasons Why Eli Lilly's Stock Likely Hasn't Peaked [Yahoo! Finance]Yahoo! Finance
- Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases [Yahoo! Finance]Yahoo! Finance
- ResMed cut at Oppenheimer after Eli Lilly's tirzepatide sleep apnea data [Seeking Alpha]Seeking Alpha
- Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 4/30/24 - Beat
LLY
Sec Filings
- 6/25/24 - Form 4
- 6/24/24 - Form 11-K
- 6/21/24 - Form 4
- LLY's page on the SEC website